# Bifidobacterium bifidum JCM 1254

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/bifidobacterium-bifidum-jcm-1254
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** Bifidobacterium bifidum JCM 1254, B. bifidum JCM 1254, Bifidobacterium bifidum strain JCM 1254, JCM 1254 strain, B. bifidum JCM1254

## Overview

Bifidobacterium bifidum JCM 1254 is a specific [probiotic](/ingredients/condition/gut-health) strain whose cell-free supernatant contains bacteriocin-like inhibitory substances and organic acids that disrupt viral replication and pathogenic bacterial membranes. Its primary mechanisms involve modulating gut mucosal [immunity](/ingredients/condition/immune-support) and producing metabolites that reduce [inflammatory](/ingredients/condition/inflammation) cytokine signaling in the cecal epithelium.

## Health Benefits

• May support recovery from antibiotic-induced gut dysbiosis - limited mouse study evidence showed reduced cecal [inflammation](/ingredients/condition/inflammation) markers after vancomycin treatment
• Potential [antiviral](/ingredients/condition/immune-support) properties - cell-free supernatant reduced Newcastle disease virus titer by 98.3% in laboratory studies only
• Supports infant gut colonization through degradation of human milk oligosaccharides - mechanistic evidence only, no human trials
• May aid in mucin degradation and [gut barrier](/ingredients/condition/gut-health) function - based on genomic analysis showing relevant enzyme genes, no clinical validation
• Possesses adherence factors for gut colonization - genomic evidence for fimbriae and collagen-binding proteins, clinical significance unknown

## Mechanism of Action

B. bifidum JCM 1254 produces a cell-free supernatant rich in short-chain fatty acids, bacteriocins, and lactic acid that lower local pH, disrupting pathogen membrane integrity and viral envelope proteins. In murine models, the strain appears to upregulate tight-junction proteins such as occludin and ZO-1, reducing [intestinal permeability](/ingredients/condition/gut-health) following antibiotic-induced dysbiosis. Its metabolites may also suppress [pro-inflammatory cytokine](/ingredients/condition/inflammation)s IL-6 and TNF-α via inhibition of NF-κB signaling in colonic epithelial cells.

## Clinical Summary

Evidence for B. bifidum JCM 1254 is currently limited to preclinical research. A mouse model demonstrated that supplementation reduced cecal [inflammation](/ingredients/condition/inflammation) markers following vancomycin-induced dysbiosis, though sample sizes were small and human translation is unconfirmed. In vitro virological assays showed the strain's cell-free supernatant reduced Newcastle disease virus titer by 98.3%, a striking result that has not been replicated in animal or human studies. No published randomized controlled trials in humans exist for this specific strain designation, making all health claims preliminary.

## Nutritional Profile

Bifidobacterium bifidum JCM 1254 is a gram-positive, non-spore-forming [probiotic](/ingredients/condition/gut-health) bacterium; its nutritional contribution derives from cellular components and metabolic byproducts rather than conventional macronutrients. Cellular dry weight is approximately 0.3–0.5 pg per cell, composed primarily of protein (~50–60% of dry weight, predominantly intracellular enzymes and structural proteins), carbohydrates (~15–25% dry weight, including cell wall peptidoglycan and exopolysaccharides), and lipids (~10–15% dry weight, primarily membrane phospholipids and glycolipids with no appreciable dietary fat contribution at typical probiotic doses of 1×10^8–1×10^10 CFU). Primary bioactive compounds include: short-chain fatty acids (SCFAs) produced via fermentation — acetate (primary end-product, typically 15–40 mM in fermentation media) and lactate (secondary product, L-lactate isomer, ~5–15 mM), with negligible butyrate production distinguishing it from some other Bifidobacterium species. Produces extracellular lacto-N-biosidase and lacto-N-tetraosidase enzymes enabling hydrolysis of human milk oligosaccharides (HMOs), specifically lacto-N-tetraose and lacto-N-neotetraose substrates. Cell wall-associated lipoteichoic acids and peptidoglycans serve as pattern-recognition ligands for TLR2/TLR6 receptors, contributing to [immunomodulatory](/ingredients/condition/immune-support) activity. Vitamin synthesis capacity is limited compared to some Bifidobacterium longum strains; B-vitamin production (folate, riboflavin) has been detected in genus-level studies but strain-specific quantitative data for JCM 1254 is not established in published literature. At standard supplement doses, direct macronutrient contribution to host nutrition is negligible (<0.1 kcal per dose); bioavailability of metabolic byproducts (SCFAs) is colonic and absorbed passively across the gut epithelium.

## Dosage & Preparation

No clinically studied dosages exist for humans. In the single mouse study, 200 μL of bacterial suspension was administered daily via oral gavage for 7 days post-antibiotic treatment, with bacterial concentration unspecified. No standardized CFU counts or commercial preparations have been studied. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Bifidobacterium bifidum strains are generally recognized as safe (GRAS) for healthy adults, with transient bloating and gas being the most commonly reported side effects during initial use. Immunocompromised individuals, including those on chemotherapy or with HIV, should consult a physician before use, as rare cases of bacteremia have been reported with [probiotic](/ingredients/condition/gut-health) strains in vulnerable populations. Concurrent use with broad-spectrum antibiotics such as vancomycin may reduce viable colony counts and diminish efficacy, so spacing administration by at least two hours is advisable. No specific safety data exist for B. bifidum JCM 1254 in pregnancy or lactation, and use during these periods should be guided by a healthcare provider.

## Scientific Research

Clinical evidence for Bifidobacterium bifidum JCM 1254 is extremely limited, with no human trials, RCTs, or meta-analyses available. The only preclinical study involved mice (n=8-10 per group) testing recovery from antibiotic-induced dysbiosis, showing modest effects on [inflammation](/ingredients/condition/inflammation) markers but limited impact on microbiota diversity restoration. No PMIDs were provided in the research dossier for the available studies.

## Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium bifidum JCM 1254. As a modern cultured strain from microbial collections, it lacks any traditional use history and represents contemporary [probiotic](/ingredients/condition/gut-health) research rather than traditional healing systems.

## Synergistic Combinations

Other Bifidobacterium strains, Lactobacillus species, [prebiotic](/ingredients/condition/gut-health)s (FOS, GOS), human milk oligosaccharides

## Frequently Asked Questions

### What makes Bifidobacterium bifidum JCM 1254 different from other B. bifidum strains?

The JCM 1254 designation refers to a specific strain deposited in the Japan Collection of Microorganisms, meaning its genome and metabolite profile are distinct from other B. bifidum isolates. Research on this strain specifically highlights potent antiviral metabolite production in its cell-free supernatant, a property that is strain-specific and cannot be assumed for generic B. bifidum supplements. Always verify that a product lists the full strain designation, not just the species name.

### Can Bifidobacterium bifidum JCM 1254 help after taking antibiotics?

Preliminary mouse research showed that B. bifidum JCM 1254 supplementation reduced cecal inflammation and helped restore microbial balance after vancomycin treatment, suggesting a role in post-antibiotic gut recovery. However, these findings come from animal models and have not been confirmed in human clinical trials, so definitive claims about antibiotic recovery in people cannot yet be made. If using a probiotic post-antibiotic, take it at least two hours after each antibiotic dose to preserve viable bacteria.

### Does Bifidobacterium bifidum JCM 1254 have antiviral properties?

In laboratory (in vitro) conditions, the cell-free supernatant of B. bifidum JCM 1254 reduced Newcastle disease virus titer by 98.3%, likely due to bacteriocin-like compounds and organic acids that degrade viral envelope structures. This result is notable but was observed only in cell culture, and Newcastle disease virus is a poultry pathogen not directly relevant to human infections. No human or animal studies have confirmed antiviral effects of this strain against human viruses.

### What is the recommended dosage for Bifidobacterium bifidum JCM 1254?

No established human clinical dosage exists for B. bifidum JCM 1254 specifically, as no randomized controlled trials have been conducted in people. General probiotic research for Bifidobacterium species typically uses doses ranging from 1 billion to 10 billion CFU (colony-forming units) per day. Until strain-specific human trials are published, dosing guidance should follow product labeling and be discussed with a healthcare provider.

### Is Bifidobacterium bifidum JCM 1254 safe for people with weakened immune systems?

Individuals with compromised immune systems, such as those undergoing immunosuppressive therapy, organ transplant recipients, or people with HIV/AIDS, face a small but real risk of probiotic-related bacteremia or sepsis with any live bacterial supplement. No specific adverse event data exist for B. bifidum JCM 1254 in immunocompromised populations, and the general caution applied to all live probiotic strains applies here. Such individuals should consult an infectious disease specialist or gastroenterologist before starting this or any probiotic supplement.

### How does Bifidobacterium bifidum JCM 1254 differ from taking a general multi-strain probiotic?

Bifidobacterium bifidum JCM 1254 is a single, clinically documented strain with specific research on human milk oligosaccharide metabolism and post-antibiotic recovery, whereas multi-strain formulas contain diverse species without strain-level characterization. Single-strain supplements allow you to target specific health goals backed by research on that exact strain, whereas multi-strain products may dilute individual strain potency across multiple organisms. For conditions like infant dysbiosis or antibiotic recovery, strain-specific evidence is more relevant than broad-spectrum formulations.

### Is Bifidobacterium bifidum JCM 1254 effective for adults, or is it primarily for infants?

While Bifidobacterium bifidum JCM 1254 has strong mechanistic evidence for infant gut colonization through milk oligosaccharide degradation, adult clinical trials are limited. The antibiotic recovery data comes from animal models rather than human studies, so efficacy in adult populations remains less established. Adults may still benefit from this strain for general gut dysbiosis, but evidence is strongest when supporting infant feeding with breast milk or HMO-supplemented formula.

### What type of research evidence exists for Bifidobacterium bifidum JCM 1254 compared to other probiotics?

Bifidobacterium bifidum JCM 1254 has mechanistic and laboratory evidence (cell culture and animal models) supporting its function, but limited human clinical trials compared to some widely-studied strains like Lactobacillus rhamnosus GG. The strongest evidence is in vitro work on antiviral activity and mouse studies on post-vancomycin inflammation, rather than large-scale randomized controlled trials in humans. For clinical decision-making, this strain should be viewed as promising but requiring more human-level research validation than established probiotics with decades of clinical data.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*